Aeglea BioTherapeutics Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Aeglea BioTherapeutics (AGLE) IPO Opens Flat
April 7, 2016 10:55 AM EDTToday's IPO for Aeglea BioTherapeutics (NASDQ: AGLE) opened for trading at $10 after pricing 5,000,000 shares of its common stock at an initial public offering price of $10 per share.
UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities are acting as joint book-running managers... More
